2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3402 Phase 1/1b trial of imetelstat and azacitidine with or without venetoclax relapsed acute myeloid leukemia (IMAGINE trial)

Douglas Tremblay, MD, Alan Shih, MD2, Jonathan Feld, MD3, Gabriela Bello, MS4, Erin Moshier5, Carly Sullivan, BSN6, Kathryn Johnson, DNP7, Christopher Swierczek8, Hannah Levavi, MD9, Marina Kremyanskaya, MD, PhD10, John O. Mascarenhas, MD11
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, Florida, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background

Patients with acute myeloid leukemia (AML) who are relapsed or refractory to standard therapies have a dismal survival of 2-3 months. Treatment options that can meaningfully impact the course of disease and produce clinical responses are urgently needed. Imetelstat is a first-in-class telomerase inhibitor approved in 2024 for patients with transfusion-dependent lower-risk myelodysplastic syndromes who are relapsed or refractory (R/R) or ineligible for erythropoiesis-stimulating agents. Importantly, telomerase is upregulated in AML blasts and associated with disease progression, making it a rational target. Imetelstat decreases AML disease burden in preclinical models, regulated by ferroptosis (Bruedigam et al Nat Cancer 2023). However, imetelstat alone failed to produce meaningful responses in R/R myelodysplastic syndrome and AML (Ades et al ASH 2025). Combination approaches of imetelstat with azacitidine (AZA) or venetoclax (VEN) have demonstrated synergy in AML cell lines and xenograft models and may significantly enhance clinical activity. In addition, imetelstat is active in several leukemia cell lines that are BCL-2 inhibitor resistant suggesting a role in relapsed AML after hypomethylating agent and venetoclax failure.

 

Methods

IMAGINE is a two-part single institution trial designed to evaluate the safety and preliminary efficacy of imetelstat in combination with AZA with or without VEN in patients with relapsed or refractory AML. The trial will consist of a safety run-in phase (Part A) enrolling 9-12 patients employing a ‘3+3’ design to monitor dose-limiting toxicities at the 5.6 mg/kg and 7.1 mg/kg dose levels of imetelstat when administered in a 28-day cycle in combination with a fixed dose of AZA (75mg/m2 days 1-7). Part B will consist of a phase 1b trial enrolling an additional 21 patients employing a BOIN12 design to determine the optimal biological dose of imetelstat, starting at a lower dose level of 4.4mg/kg and escalating to 5.6mg/kg and 7.1mg/kg, in combination with a fixed dose of AZA and VEN (14 days). Response assessments will occur after C2, C4 and C6.

 

Eligible patients have relapsed AML without available standard treatment options and inclusion is mutation agnostic. The primary objective for Part A is to determine the safety of the doublet (AZA+imetelstat) before moving on to the Part B triplet therapy (AZA+VEN+imetelstat), with a primary objective of identifying the optimal biological dose (OBD) of imetelstat with azacitidine and venetoclax. Secondary objectives include efficacy metrics including composite complete response rates, duration of response, and overall survival. Exploratory analysis will assess the mutational burden with treatment as well as telomere length and measurement of ferroptosis during treatment.

 

The trial is open to accrual at Mount Sinai (NCT07320235) and enrollment is ongoing.

Douglas Tremblay, MD: Cogent - Research Funding; Oryzon - Research Funding; Sobi - Research Funding; Geron - Research Funding; Blueprint - Research Funding; AbbVie - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Pharmaessentia - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony)